Aldactone Related Published Studies
Well-designed clinical trials related to Aldactone (Spironolactone)
Comparison of the efficacy of 5% topical spironolactone gel and placebo in the
treatment of mild and moderate acne vulgaris: a randomized controlled trial. [2012]
Rationale and design of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist Trial: A randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction. [2011.12]
Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT): a randomized, double-blind, placebo-controlled trial. [2011.06]
A double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism. [2011.05]
Effects of spironolactone on cardiac sympathetic nerve activity and left ventricular remodelling after reperfusion therapy in patients with first ST-segment elevation myocardial infarction. [2011.05]
Spironolactone does not prevent acute mountain sickness: a prospective, double-blind, randomized, placebo-controlled trial by SPACE Trial Group (spironolactone and acetazolamide trial in the prevention of acute mountain sickness group). [2011.03]
Effects of mineralocorticoid receptor antagonist spironolactone on atrial conduction and remodeling in patients with heart failure. [2011.03]
Efficacy of low dose spironolactone in chronic kidney disease with resistant hypertension. [2011.01]
Effect of combined spironolactone-beta-blocker +/- enalapril treatment on occurrence of symptomatic atrial fibrillation episodes in patients with a history of paroxysmal atrial fibrillation (SPIR-AF study). [2010.12.01]
Spironolactone use at discharge was associated with improved survival in hospitalized patients with systolic heart failure. [2010.12]
Spironolactone in preventing hypokalemia following traumatic brain injury. [2010.12]
The effects of spironolactone on atrial remodeling in patients with preserved left ventricular function after an acute myocardial infarction: a randomized follow-up study. [2010.12]
Effect of spironolactone on left ventricular systolic and diastolic function in patients with early stage chronic kidney disease. [2010.11.15]
Effect of spironolactone on left ventricular ejection fraction and volumes in patients with class I or II heart failure. [2010.11.01]
Effect of eplerenone versus spironolactone on cortisol and hemoglobin A(c) levels in patients with chronic heart failure. [2010.11]
The effect of spironolactone upon corticosteroid hormone metabolism in patients with early stage chronic kidney disease. [2010.11]
Comparison of the efficacy of 5% topical spironolactone gel and placebo in the treatment of mild and moderate acne vulgaris: a randomized controlled trial. [2010.10.22]
Rationale and design of the 'aldosterone receptor blockade in diastolic heart failure' trial: a double-blind, randomized, placebo-controlled, parallel group study to determine the effects of spironolactone on exercise capacity and diastolic function in patients with symptomatic diastolic heart failure (Aldo-DHF). [2010.08]
A randomized, double-blind, placebo-controlled trial of spironolactone on carotid intima-media thickness in nondiabetic hemodialysis patients. [2010.08]
Spironolactone and hydrochlorothiazide decrease vascular stiffness and blood pressure in geriatric hypertension. [2010.07]
Efficacy of spironolactone on survival in dogs with naturally occurring mitral regurgitation caused by myxomatous mitral valve disease. [2010.03]
Oral contraceptives alone and with spironolactone increase sCD40 ligand in PCOS patients. [2010.03]
The effect of spironolactone on sweat and urinary sodium excretion during exercise in humans. [2010.01]
Spironolactone and hydrochlorothiazide decrease vascular stiffness and blood
pressure in geriatric hypertension. [2010]
Comparison of effects of low dose of spironolactone and a thiazide diuretic in patients with hypertension treated with an angiotensin-converting enzyme inhibitor or an angiotensin type 1 receptor blocker. [2009.11]
Spironolactone and chlorthalidone in uncontrolled elderly hypertensive patients treated with calcium antagonists and angiotensin II receptor-blocker: effects on endothelial function, inflammation, and oxidative stress. [2009.10]
Treatment with spironolactone for 24 weeks decreases the level of matrix metalloproteinases and improves cardiac function in patients with chronic heart failure of ischemic etiology. [2009.09]
Effect of spironolactone on left ventricular mass and aortic stiffness in early-stage chronic kidney disease: a randomized controlled trial. [2009.08.04]
Spironolactone in chronic hemodialysis patients improves cardiac function. [2009.05]
Differential effects of chlorthalidone versus spironolactone on muscle sympathetic nerve activity in hypertensive patients. [2009.04]
Antifibrotic effects of aldosterone receptor blocker (spironolactone) in patients with chronic kidney disease. [2009]
Effects of additive therapy with spironolactone on proteinuria in diabetic patients already on ACE inhibitor or ARB therapy: results of a randomized, placebo-controlled, double-blind, crossover trial. [2008.04]
Comparison of the clinical efficacy of flutamide and spironolactone plus ethinyloestradiol/cyproterone acetate in the treatment of hirsutism: a randomised controlled study. [2008.04]
Hemodynamic effects of propranolol with spironolactone in patients with variceal bleeds: A randomized controlled trial. [2008.03.28]
Spironolactone versus eplerenone for the treatment of idiopathic hyperaldosteronism. [2008.03]
The Spironolactone, Amiloride, Losartan, and Thiazide (SALT) double-blind crossover trial in patients with low-renin hypertension and elevated aldosterone-renin ratio. [2007.07.17]
Does the aldosterone: renin ratio predict the efficacy of spironolactone over bendroflumethiazide in hypertension? A clinical trial protocol for RENALDO (RENin-ALDOsterone) study. [2007.05.09]
Effect of spironolactone on blood pressure in subjects with resistant hypertension. [2007.04]
[Efficacy and safety of long-term application of spironolactone in patients with moderate and severe chronic heart failure receiving optimal therapy] [2007]
Effect of treatment of rosacea in females by Chibixiao Recipe in combination with minocycline and spironolactone. [2006.12]
Spironolactone in type 2 diabetic nephropathy: Effects on proteinuria, blood pressure and renal function. [2006.11]
Effects of spironolactone during an angiotensin II receptor blocker treatment on the left ventricular mass reduction in hypertensive patients with concentric left ventricular hypertrophy. [2006.08]
Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy. [2006.08]
Spironolactone further reduces urinary albumin excretion and plasma B-type natriuretic peptide levels in hypertensive type II diabetes treated with angiotensin-converting enzyme inhibitor. [2006.05]
Spironolactone treatment and clinical outcomes in patients with systolic dysfunction and mild heart failure symptoms: a retrospective analysis. [2006.05]
Appropriateness of spironolactone prescribing in heart failure patients: a population-based study. [2006.04]
Double-blind, placebo-controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy, with or without an angiotensin II receptor blocker. [2006.03]
Comparison of the clinical efficacy of flutamide and spironolactone plus Diane 35 in the treatment of idiopathic hirsutism: a randomized controlled study. [2005.12]
Beneficial impact of spironolactone in diabetic nephropathy. [2005.12]
Comparative pilot study of repeated large volume paracentesis vs the combination on clonidine-spironolactone in the treatment of cirrhosis-associated refractory ascites. [2005.11]
Spironolactone improves diastolic function in the elderly. [2005.10]
Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study. [2005.09]
Effect of spironolactone on blood pressure and the renin-angiotensin-aldosterone system in oligo-anuric hemodialysis patients. [2005.07]
Spironolactone reduces brachial pulse wave velocity and PIIINP levels in hypertensive diabetic patients. [2005.05]
Effect of losartan and spironolactone on left ventricular mass and heart sympathetic activity in prehypertensive obese subjects: a 16-week randomized trial. [2005.04]
Spironolactone improves lung diffusion in chronic heart failure. [2005.01]
Well-designed clinical trials possibly related to Aldactone (Spironolactone)
A double-blind, randomized, parallel, placebo-controlled study examining the
effect of cross-linked polyelectrolyte in heart failure patients with chronic
kidney disease. [2012]
A randomized trial on mineralocorticoid receptor blockade in men: effects on stress responses, selective attention, and memory. [2011.12]
Pharmacotherapy review of chronic pediatric hypertension. [2011.10]
Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial. [2011.04]
Eplerenone in patients with systolic heart failure and mild symptoms. [2011.01.06]
Truncated areas under the curve in the assessment of pioglitazone bioequivalence. Data from a single-center, single-dose, randomized, open-label, 2-way cross-over bioequivalence study of two formulations of pioglitazone 45 mg tablets under fasting conditions. [2011]
The efficacy and safety of the novel aldosterone antagonist eplerenone in children with hypertension: a randomized, double-blind, dose-response study. [2010.08]
Effects of a selective vasopressin V2 receptor antagonist, satavaptan, on ascites recurrence after paracentesis in patients with cirrhosis. [2010.08]
Microvascular obstruction remains a portent of adverse remodeling in optimally treated patients with left ventricular systolic dysfunction after acute myocardial infarction. [2010.07.01]
Microvascular obstruction remains a portent of adverse remodeling in optimally treated patients with left ventricular systolic dysfunction after acute myocardial infarction. [2010.07]
Rationale and design of the Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure (EMPHASIS-HF). [2010.06]
Rationale and design of the Eplerenone combination Versus conventional Agents to Lower blood pressure on Urinary Antialbuminuric Treatment Effect (EVALUATE) trial: a double-blinded randomized placebo-controlled trial to evaluate the antialbuminuric effects of an aldosterone blocker in hypertensive patients with albuminuria. [2010.06]
Impact of aldosterone receptor blockade compared with thiazide therapy on sympathetic nervous system function in geriatric hypertension. [2010.05]
Randomized, double-blind, multicenter, placebo-controlled study evaluating the effect of aldosterone antagonism with eplerenone on ventricular remodeling in patients with mild-to-moderate heart failure and left ventricular systolic dysfunction. [2010.05]
Tissue plasminogen activator antigen predicts medium-term left ventricular end-systolic volume after acute myocardial infarction. [2010.05]
Renal function in outpatients with chronic heart failure. [2010.05]
Clinical trial: short-term effects of combination of satavaptan, a selective vasopressin V2 receptor antagonist, and diuretics on ascites in patients with cirrhosis without hyponatraemia--a randomized, double-blind, placebo-controlled study. [2010.04]
Intensive versus conventional therapy to slow the progression of idiopathic glomerular diseases. [2010.04]
Modulation of the mineralocorticoid receptor as add-on treatment in depression: a randomized, double-blind, placebo-controlled proof-of-concept study. [2010.04]
Effect of combined angiotensin-converting enzyme and aldosterone inhibition on plasma plasminogen activator inhibitor type 1 levels in chronic hypertensive patients. [2010.03]
N-terminal pro-B-type natriuretic peptide-guided, intensive patient management in addition to multidisciplinary care in chronic heart failure a 3-arm, prospective, randomized pilot study. [2010.02.16]
Baseline plasma NT-proBNP and clinical characteristics: results from the irbesartan in heart failure with preserved ejection fraction trial. [2010.02]
Serum soluble ST2: a potential novel mediator in left ventricular and infarct remodeling after acute myocardial infarction. [2010.01.19]
Does the ratio of serum aldosterone to plasma renin activity predict the efficacy of diuretics in hypertension? Results of RENALDO. [2010.01]
A population approach to eplerenone pharmacokinetics and saturable protein binding. [2010]
The efficacy and safety of the novel aldosterone antagonist eplerenone in
children with hypertension: a randomized, double-blind, dose-response study. [2010]
Rationale and design of the Eplerenone in Mild Patients Hospitalization And
SurvIval Study in Heart Failure (EMPHASIS-HF). [2010]
Baseline plasma NT-proBNP and clinical characteristics: results from the
irbesartan in heart failure with preserved ejection fraction trial. [2010]
Modulation of the mineralocorticoid receptor as add-on treatment in depression: a
randomized, double-blind, placebo-controlled proof-of-concept study. [2010]
Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy. [2009.12]
Timing of eplerenone initiation and outcomes in patients with heart failure after acute myocardial infarction complicated by left ventricular systolic dysfunction: insights from the EPHESUS trial. [2009.11]
Natural history of markers of collagen turnover in patients with early diastolic dysfunction and impact of eplerenone. [2009.10.27]
The effects of eplerenone on length of stay and total days of heart failure hospitalization after myocardial infarction in patients with left ventricular systolic dysfunction. [2009.09]
Relationships between cardiac resynchronization therapy and N-terminal pro-brain natriuretic peptide in patients with heart failure and markers of cardiac dyssynchrony: an analysis from the Cardiac Resynchronization in Heart Failure (CARE-HF) study. [2009.09]
Role of vasopressin and aldosterone in pulmonary arterial hypertension: A pilot study. [2009.09]
Plasma Renin test-guided drug treatment algorithm for correcting patients with treated but uncontrolled hypertension: a randomized controlled trial. [2009.07]
Usefulness of abnormal heart rate turbulence to predict cardiovascular mortality in high-risk patients with acute myocardial infarction and left ventricular dysfunction (from the EPHESUS study). [2009.06.01]
Left ventricular remodeling after acute myocardial infarction: does eplerenone have an effect? [2009.06]
Plasma apelin concentration is depressed following acute myocardial infarction in man. [2009.06]
A history of systemic hypertension and incident heart failure hospitalization in patients with acute myocardial infarction and left ventricular systolic dysfunction. [2009.05.15]
Extracellular cardiac matrix biomarkers in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) study. [2009.05.12]
Mechanisms of impaired potassium handling with dual renin-angiotensin-aldosterone blockade in chronic kidney disease. [2009.05]
Combined receptor antagonist stimulation of the hypothalamic-pituitary-adrenal axis test identifies impaired negative feedback sensitivity to cortisol in obese men. [2009.04]
Aldosterone blockade and left ventricular dysfunction: a systematic review of randomized clinical trials. [2009.02]
Patient health status and costs in heart failure: insights from the eplerenone post-acute myocardial infarction heart failure efficacy and survival study (EPHESUS). [2009.01.27]
|
